logo

For the Inventor, By the Inventor

Newark, CA, United States of America

Mary Shen

USPTO Granted Patents = 13

Average Co-Inventor Count = 4.1

ph-index = 2

Forward Citations = 212(Granted Patents)


Company Filing History:

goldMedal13 out of 488 
 
Rigel Pharmaceuticals, Incorporated
 patents

Years Active: 2002-2011

Loading Chart...
13 patents (USPTO):Explore Patents
1. 7863222 - shRNA library (2011-01-04),
2. 7488805 - Apoptosis proteins (2009-02-10),
3. 7423118 - IAPS associated cell cycle proteins, compositions and methods of use (2008-09-09),
4. 7420045 - IAPs associated cell cycle proteins, compositions and methods of use (2008-09-02),
5. 7223850 - Apoptosis proteins (2007-05-29),
6. 7034145 - Directionally cloned random cDNA expression vector libraries, compositions and methods of use (2006-04-25),
7. 7001732 - RIP3 associated cell cycle protein (2006-02-21),
8. 6808906 - Directionally cloned random cDNA expression vector libraries, compositions and methods of use (2004-10-26),
9. 6737232 - IAPs associated cell cycle proteins, compositions and methods of use (2004-05-18),
10. 6623980 - Exo1 and Exo2, exocytotic proteins (2003-09-23),
11. 6569658 - Germinal center kinase cell cycle proteins (2003-05-27),
12. 6562591 - Germinal center kinase cell cycle proteins, compositions and methods of use (2003-05-13),
13. 6428980 - Nucleic acids encoding RIP3 associated cell cycle proteins (2002-08-06),

Title: Innovator Spotlight: Mary Shen

Introduction

Mary Shen is an accomplished inventor based in Newark, CA, known for her significant contributions to the field of biotechnology. With a remarkable portfolio of 13 patents, she has demonstrated her expertise in developing innovative solutions that advance scientific research and therapeutic applications.

Latest Patents

Among her latest innovations is the development of an shRNA library, which involves a library of nucleic acid vectors along with a method for its creation. This library comprises various nucleic acid molecules designed for specific functionalities, featuring components that are at least 15 nucleotides long and complementary to each other. Additionally, she has delivered groundbreaking work on apoptosis proteins, including Apop1, Apop2, and Apop3. This invention focuses on novel polypeptides that modulate apoptosis, providing insights into their biological roles. Furthermore, her work includes methods for identifying compositions that can influence the biological activities of these apoptosis proteins, thus holding potential for applications in disease diagnosis and treatment.

Career Highlights

Mary Shen currently works at Rigel Pharmaceuticals, Incorporated, where she is engaged in pioneering research and development efforts. Her career highlights showcase her commitment to advancing medical science through innovative biotechnological solutions.

Collaborations

Throughout her career, Mary has collaborated with talented coworkers, including Ying Luo and Betty Huang, fostering an environment of creativity and innovation. These partnerships have significantly contributed to the progression and success of her research projects.

Conclusion

Mary Shen's dedication to innovation and her extensive patent portfolio illustrate her impact on the field of biotechnology. Her work not only enhances current scientific understanding but also paves the way for potential breakthroughs in medical treatments, exemplifying the vital role of inventors in shaping the future of healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…